JPRN-UMIN000015409
Recruiting
未知
molecular based analysis and novel therapies development of chronic myelocytic leukemia - molecular based analysis and novel therapies development of chronic myelocytic leukemia
Keio University School of Medicine, Division of Hematology0 sites200 target enrollmentOctober 14, 2014
Conditionschronic myelocytic leukemia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- chronic myelocytic leukemia
- Sponsor
- Keio University School of Medicine, Division of Hematology
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 Can not consent in writing 2 physician deems disqualify
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
Evaluation of levels of Biomarkers in different stages of PulpitisHealth Condition 1: K040- PulpitisCTRI/2023/11/059706Manipal College of Dental Sciences
Active, not recruiting
Not Applicable
Dietary supplements, exercise, and muscle ageingISRCTN23294745niversity of Bradford420
Withdrawn
Not Applicable
A search for novel therapeutic targets and biomarkers in patients with Systemic Lupus ErythematosusSLEsystemic lupus erythematosus10003816NL-OMON36575niversitair Medisch Centrum Utrecht75
Recruiting
Not Applicable
Clinical studies to elucidate the molecular mechanisms associated with the pathogenesis of amyotrophic lateral sclerosis (ALS) and to identify effective drug targetsAmyotrophic lateral sclerosisJPRN-UMIN000051823Keio University, School of Medicine600
Completed
Not Applicable
Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in GermanyU07.1COVID-19, virus identifiedDRKS00021270Krankenhaus Reinbek St. Adolf-Stift871